Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.

ABSTRACT:

Background

The common inflammatory disease multiple sclerosis (MS) is a disease of the central nervous system. For more than 25 years autologous hematopoietic stem cell transplantation (AHSCT) has been used to treat MS. It has been shown to be highly effective in suppressing inflammatory activity in relapsing-remitting MS (RRMS) patients. This treatment is thought to lead to an immune system reset, inducing a new, more tolerant system; however, the precise mechanism behind the treatment effect in MS patients is unknown. In this study, the effect of AHSCT on the metabolome and lipidome in peripheral blood from RRMS patients was investigated.

Methods

Peripheral blood samples were collected from 16 patients with RRMS at ten-time points over the five months course of AHSCT and 1

SUBMITTER: Vaivade A 

PROVIDER: S-EPMC10327322 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature